Cargando…

Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)

BACKGROUND: Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). METHODS: The cu...

Descripción completa

Detalles Bibliográficos
Autores principales: Topchu, Iuliia, Karnaukhov, Nikolai, Mazitova, Alexandra, Yugai, Veronika, Voloshin, Mark, Tikhomirova, Mariya, Kit, Oleg, Frantsiyants, Elena, Kharin, Leonid, Airapetova, Tamara, Ratner, Ekaterina, Sabirov, Alexey, Abramova, Zinaida, Serebriiskii, Iliya, Boumber, Yanis, Deneka, Alexander
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024834/
https://www.ncbi.nlm.nih.gov/pubmed/33841930
http://dx.doi.org/10.21037/jtd-20-2787
_version_ 1783675391555141632
author Topchu, Iuliia
Karnaukhov, Nikolai
Mazitova, Alexandra
Yugai, Veronika
Voloshin, Mark
Tikhomirova, Mariya
Kit, Oleg
Frantsiyants, Elena
Kharin, Leonid
Airapetova, Tamara
Ratner, Ekaterina
Sabirov, Alexey
Abramova, Zinaida
Serebriiskii, Iliya
Boumber, Yanis
Deneka, Alexander
author_facet Topchu, Iuliia
Karnaukhov, Nikolai
Mazitova, Alexandra
Yugai, Veronika
Voloshin, Mark
Tikhomirova, Mariya
Kit, Oleg
Frantsiyants, Elena
Kharin, Leonid
Airapetova, Tamara
Ratner, Ekaterina
Sabirov, Alexey
Abramova, Zinaida
Serebriiskii, Iliya
Boumber, Yanis
Deneka, Alexander
author_sort Topchu, Iuliia
collection PubMed
description BACKGROUND: Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). METHODS: The current study included 40 patients with NSCLC, of whom one presented with stage 1, 14 presented with stage II, 15 presented with stage III, and 10 patients had stage IV. All patients received standard of care treatments. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 protein expression in matching specimens of normal lung versus tumor tissues, and primary versus metastatic tumors, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed in silico using publicly available datasets (TCGA/ICGC and KM plots). RESULTS: MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors versus normal lung tissue (P=0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (P=0.026) combined for all stages and with overall survival (OS) at stage IV (P=0.013). Elevated MSI2 expression on RNA level was confirmed in primary tumor versus normal tissue samples in TCGA dataset (P<0.0001), and positively correlated with decreased OS (P=0.02). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type. CONCLUSIONS: Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are warranted.
format Online
Article
Text
id pubmed-8024834
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-80248342021-04-08 Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC) Topchu, Iuliia Karnaukhov, Nikolai Mazitova, Alexandra Yugai, Veronika Voloshin, Mark Tikhomirova, Mariya Kit, Oleg Frantsiyants, Elena Kharin, Leonid Airapetova, Tamara Ratner, Ekaterina Sabirov, Alexey Abramova, Zinaida Serebriiskii, Iliya Boumber, Yanis Deneka, Alexander J Thorac Dis Original Article BACKGROUND: Musashi-2 (MSI2) is a member of RNA-binding protein family that regulates mRNA translation of numerous intracellular targets and influences maintenance of stem cell identity. This study assessed MSI2 as a potential clinical biomarker in non-small cell lung cancer (NSCLC). METHODS: The current study included 40 patients with NSCLC, of whom one presented with stage 1, 14 presented with stage II, 15 presented with stage III, and 10 patients had stage IV. All patients received standard of care treatments. All patient samples were obtained before treatment started. We used immunohistochemical (IHC) approach to measure MSI2 protein expression in matching specimens of normal lung versus tumor tissues, and primary versus metastatic tumors, followed by correlative analysis in relation to clinical outcomes. In parallel, clinical correlative analysis of MSI2 mRNA expression was performed in silico using publicly available datasets (TCGA/ICGC and KM plots). RESULTS: MSI2 protein expression in patient samples was significantly elevated in NSCLC primary tumors versus normal lung tissue (P=0.03). MSI2 elevated expression positively correlated with a decreased progression free survival (PFS) (P=0.026) combined for all stages and with overall survival (OS) at stage IV (P=0.013). Elevated MSI2 expression on RNA level was confirmed in primary tumor versus normal tissue samples in TCGA dataset (P<0.0001), and positively correlated with decreased OS (P=0.02). No correlation was observed between MSI2 expression and age, sex, smoking, and treatment type. CONCLUSIONS: Elevated MSI2 expression in primary NSCLC tumors is associated with poor prognosis and can be used as a novel potential prognostic biomarker in NSCLC patients. Future studies in an extended patient cohort are warranted. AME Publishing Company 2021-03 /pmc/articles/PMC8024834/ /pubmed/33841930 http://dx.doi.org/10.21037/jtd-20-2787 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Topchu, Iuliia
Karnaukhov, Nikolai
Mazitova, Alexandra
Yugai, Veronika
Voloshin, Mark
Tikhomirova, Mariya
Kit, Oleg
Frantsiyants, Elena
Kharin, Leonid
Airapetova, Tamara
Ratner, Ekaterina
Sabirov, Alexey
Abramova, Zinaida
Serebriiskii, Iliya
Boumber, Yanis
Deneka, Alexander
Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)
title Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)
title_full Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)
title_fullStr Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)
title_full_unstemmed Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)
title_short Musashi 2 (MSI2) expression as an independent prognostic biomarker in non-small cell lung cancer (NSCLC)
title_sort musashi 2 (msi2) expression as an independent prognostic biomarker in non-small cell lung cancer (nsclc)
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8024834/
https://www.ncbi.nlm.nih.gov/pubmed/33841930
http://dx.doi.org/10.21037/jtd-20-2787
work_keys_str_mv AT topchuiuliia musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT karnaukhovnikolai musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT mazitovaalexandra musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT yugaiveronika musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT voloshinmark musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT tikhomirovamariya musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT kitoleg musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT frantsiyantselena musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT kharinleonid musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT airapetovatamara musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT ratnerekaterina musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT sabirovalexey musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT abramovazinaida musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT serebriiskiiiliya musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT boumberyanis musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc
AT denekaalexander musashi2msi2expressionasanindependentprognosticbiomarkerinnonsmallcelllungcancernsclc